FY2025 EPS Estimates for MariMed Reduced by Noble Financial

MariMed Inc. (OTCMKTS:MRMD) – Analysts at Noble Financial cut their FY2025 earnings estimates for shares of MariMed in a research report issued on Monday, May 12th. Noble Financial analyst J. Gomes now expects that the company will post earnings of ($0.04) per share for the year, down from their prior forecast of ($0.01). Noble Financial has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for MariMed’s FY2026 earnings at ($0.02) EPS.

MariMed Price Performance

Shares of MRMD opened at $0.09 on Wednesday. The business has a 50-day moving average of $0.10 and a 200-day moving average of $0.12. MariMed has a 1 year low of $0.07 and a 1 year high of $0.29. The company has a market capitalization of $33.23 million, a price-to-earnings ratio of -2.14 and a beta of 3.15. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.55 and a quick ratio of 0.73.

MariMed (OTCMKTS:MRMD) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). MariMed had a negative return on equity of 2.75% and a negative net margin of 10.97%. The business had revenue of $37.96 million during the quarter, compared to the consensus estimate of $38.33 million.

MariMed Company Profile

MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand.